S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:TLRY - Tilray Stock Price, Forecast & News

$18.19
-0.36 (-1.94 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$18.07
Now: $18.19
$18.88
50-Day Range
$18.16
MA: $21.07
$25.41
52-Week Range
$18.00
Now: $18.19
$106.00
Volume1.24 million shs
Average Volume1.91 million shs
Market Capitalization$1.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta4.07
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLRY
CUSIPN/A
CIKN/A
Phone844-845-7291

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.13 million
Book Value$2.12 per share

Profitability

Net Income$-67,720,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.83 billion
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive TLRY News and Ratings via Email

Sign-up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter.


Tilray (NASDAQ:TLRY) Frequently Asked Questions

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) announced its earnings results on Tuesday, November, 12th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.05. The business earned $51.10 million during the quarter, compared to analysts' expectations of $49.57 million. Tilray had a negative return on equity of 40.30% and a negative net margin of 97.39%. Tilray's quarterly revenue was up 411.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.08) EPS. View Tilray's Earnings History.

When is Tilray's next earnings date?

Tilray is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Tilray.

What price target have analysts set for TLRY?

18 brokerages have issued 12-month target prices for Tilray's shares. Their forecasts range from $20.00 to $81.10. On average, they anticipate Tilray's stock price to reach $42.72 in the next year. This suggests a possible upside of 134.9% from the stock's current price. View Analyst Price Targets for Tilray.

What is the consensus analysts' recommendation for Tilray?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 3 sell ratings, 11 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tilray.

What are Wall Street analysts saying about Tilray stock?

Here are some recent quotes from research analysts about Tilray stock:
  • 1. According to Zacks Investment Research, "Tilray, Inc. is a pharmaceutical company. It develops cannabis based medicines, drugs, drops and oil products. Tilray, Inc. is based in NANAIMO, Canada. " (10/25/2019)
  • 2. Jefferies Financial Group Inc analysts commented, "We initiate at Underperform, PT $61. With arguably inferior positioning in parts of its business vs. certain peers (questionable Canada rec approach, less impressive US optionality, too much value credited to ABI/ABG), we struggle to justify the current valuation. We appreciate it is well placed in medical but future value here will be driven by IP for which little visibility near term. Its share structure also raises risk of increased volatility." (3/8/2019)

Has Tilray been receiving favorable news coverage?

News headlines about TLRY stock have trended somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tilray earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Tilray.

Are investors shorting Tilray?

Tilray saw a drop in short interest during the month of November. As of November 29th, there was short interest totalling 7,800,000 shares, a drop of 13.2% from the November 14th total of 8,990,000 shares. Based on an average daily trading volume, of 1,540,000 shares, the short-interest ratio is currently 5.1 days. Approximately 31.4% of the company's stock are short sold. View Tilray's Current Options Chain.

Who are some of Tilray's key competitors?

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Advanced Micro Devices (AMD), GW Pharmaceuticals PLC- (GWPH) and Aphria (APHA).

Who are Tilray's key executives?

Tilray's management team includes the folowing people:
  • Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
  • Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
  • Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
  • Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Who are Tilray's major shareholders?

Tilray's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SG Americas Securities LLC (0.15%), Commerzbank Aktiengesellschaft FI (0.05%), Man Group plc (0.04%), State Street Corp (0.03%), Commonwealth Equity Services LLC (0.03%) and Virtu Financial LLC (0.03%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda and Michael Auerbach. View Institutional Ownership Trends for Tilray.

Which major investors are selling Tilray stock?

TLRY stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives, Great West Life Assurance Co. Can, State Street Corp and Creative Planning. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda and Michael Auerbach. View Insider Buying and Selling for Tilray.

Which major investors are buying Tilray stock?

TLRY stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Commerzbank Aktiengesellschaft FI, Man Group plc, Virtu Financial LLC, Baker Avenue Asset Management LP, Cambridge Investment Research Advisors Inc., Sigma Planning Corp and Penserra Capital Management LLC. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy and Edward Wood Pastorius Jr. View Insider Buying and Selling for Tilray.

How do I buy shares of Tilray?

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $18.19.

How big of a company is Tilray?

Tilray has a market capitalization of $1.83 billion and generates $43.13 million in revenue each year. The company earns $-67,720,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. View Additional Information About Tilray.

What is Tilray's official website?

The official website for Tilray is http://www.tilray.com/.

How can I contact Tilray?

Tilray's mailing address is 1100 Maughan Road, Nanaimo A1, V9X IJ2. The company can be reached via phone at 844-845-7291.


MarketBeat Community Rating for Tilray (NASDAQ TLRY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  388 (Vote Outperform)
Underperform Votes:  425 (Vote Underperform)
Total Votes:  813
MarketBeat's community ratings are surveys of what our community members think about Tilray and other stocks. Vote "Outperform" if you believe TLRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel